Effects of silencing MTA1 gene by RNA interference on invasion and metastasis of endometrial carcinoma

Objective: The study aimed at the silence effect of MAT1 gene and proteins in Ishikawa cell of human endometrial carcinoma cell line through RNAi mediated by siRNA and also discussed the effect of MTA1 gene silence on the invasion and metastasis of endometrial carcinoma. Materials and Methods: According to the principle of designing siRNA sequence, siRNA aiming at MTA1 gene (MTA1- siRNA) and siRNA used for negative control (Control-siRNA) were designed and synthesized and Ishikawa cell was transfected by transfection reagents. RT-PCR method as well as western blot was used, respectively, to detect the MTA1 mRNA and protein expression of stably transfected cells. Transwell method and scarification experiment were adopted to detect the invasion and metastasis of Ishikawa cells. Results: The expression results of MTA1 on the levels of mRNA and protein showed that the expression level in transfected MTA1-siRNA group was obviously lower than that in non-transfected group and transfected control-siRNA group (p < 0.05), while there was no significant difference between non-transfected group and transfected control-siRNA group (p > 0.05). Effective interference on the expression of MTA1 gene remarkably lowered the invasion and metastasis of endometrial carcinoma Ishikawa cells. Conclusion: RNAi aiming at MTA1 can effectively inhibit the expression of MTA1 in endometrial carcinoma Ishikawa cells and the effective silence of MTA1 can weaken the invasion and metastasis of Ishikawa cells, which provides a new strategy for gene therapy of endometrial carcinoma and an experimental basis for inhibiting the invasion and metastasis of endometrial carcinoma.

[1] Nicolaije K.A., Ezendam N.P., Vos M.C., Boll D., Pijnenborg J.M., Kruitwagen R.F., et al.: “Follow-up practice in endometrial cancer and the association with patient and hospital characteristics: A study from the population-based PROFILES registry”. Gynecol. Oncol., 2013, 129, 324.

[2] Zhou H.H., Liu J.: “Gene targeting tailored therapy for the anti-tumor drugs”. Anti-tumor Pharmacy, 2011, 1, 6.

[3] Pencil S.D., Toh Y., Nicolson G.L.: “Candidate metastasis- associated genes of the rat 13762NF mammary adenocatcinoma”. Breast Cancer Res. Treat.,1993, 25, 165.

[4] Li D.Q., Pakala S.B., Reddy S.D., Peng S., Balasenthil S., Deng C. X., et al.: “Metastasis- associated protein 1 is an integral component of the circadian molecular machinery”. Nat. Commun., 2013, 4, 2545. doi: 10.1038/ncomms3545.

[5] Nicolson G.L., Nawa A., Toh Y., Taniguchi S., Nishimori K., Moustafa A.: “Tumor metastasis associated human MTA1 gene and its MTA1 protein product role in epithelial cancer cell invasion, proliferation and nuclear regulation”. Clin. Exp. Metastasis, 2003, 20, 19.

[6] Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I.: “Endometrial cancer”. Lancet, 2005, 366, 491.

[7] Zhu X., Guo Y., Li X., Ding Y, Chen L.: “Metastasis-associated protein 1 nuclear expression is associated with tumor progression and clinical outcome in patients with nonsmall cell lung cancer”. Thorac. Oncol., 2010, 5, 1159.

[8] Pakala S.B., Rayala S.K., Wang R.A., Ohshiro K., Mudvari P., Reddy S.D., et al.: “MTA1 promotes STAT3 transcription and pulmonary metastasis in breast cancer”. Cancer Res., 2013, 73, 37761.

[9] Kai L., Wang J., Ivanovic M., Chung Y.T., Laskin W.B., Schulze-Hoepfner F., et al.: “Targeting prostate cancer angiogenesis through metastasis-assiated protein 1(MTA1)”. Prostate, 2011, 71, 268.

[10] Hofer M., Chang M.C., Hirko K.A., Rubin M.A., Nosé V.: “Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1(MTA1) expression in benign and malignant pancreatic endocrine tumors”. Mod. Pathol., 2009, 22, 933.

[11] Murakami M., Kaul R., Robertson E.: “MTA1 expression is linked to ovarian cancer”. Cancer Biol. Ther., 2008, 7, 1468.

[12] Mahoney M.G., Simpson A., Jost M., Noé M., Kari C., Pepe D., et al.: “Metastasis associated protein 1(MTA1) enhances metastasis, invasion and anchorage independent survival of immortalized human keratinocytes”. Oncogene, 2002, 21, 2161.

[13] Balasenthil S., Broaddus R.R., Kumar R.: “Expression of metastasis-associated protein 1(MTA1) in benign endometrium and endometrial adenocarcinomas”. Hum. Pathol., 2006, 37, 656.

[14] Pan J.L., Han S.P.: “Expression of MTA1 protein in carcinoma of endometrium”. Journal of Clinical Medicine in Practice, 2007, 11, 32.

[15] Zhang S.L., Hao Q., Sun H.X., Feng H., Ju B.H., Tian J.: “Effects of MTAI on invasion and metastasis of endometrial cacinoma cell”. Chinese Journal of Clinical Oncology, 2012, 39, 630.

[16] Zhang S.L., Hao Q., Sun H.X., Feng H., Ju B.H., Tian J.: “Correlation studies between MTA1 protein expression and endometrial carcinoma”. Chinese Journal of Clinical Oncology, 2012, 39, 208.